Biologics vs JAK Inhibitors for RA: Safety Compared

Research-informed explainer — last updated 2026-04-11

If your rheumatologist has suggested moving beyond methotrexate for your rheumatoid arthritis, two drug classes will likely come up: biologics and JAK inhibitors. Both suppress the overactive immune response that damages your joints. Both carry real risks. But their risk profiles differ in specific ways that matter a lot depending on your age, heart health, and medical history — and the guidelines that rheumatologists follow have shifted in recent years.

This explainer draws on peer-reviewed research from rheumatologists listed in the Convene directory, including specialists who co-authored the EULAR and ACR guidelines that shape how these drugs are prescribed today.

What are biologics and JAK inhibitors?

Biologics are injectable medications made from proteins. They work by intercepting specific molecules in the immune system that drive joint inflammation. The most common type targets TNF (tumor necrosis factor), a protein that tells immune cells to attack. TNF inhibitors like etanercept and adalimumab were among the first biologics developed for RA. Others target different pathways, including the IL-6 receptor and a protein called CD20 on immune cells. Biologics are given by injection or infusion — either at home or in a clinic, depending on the specific drug.

JAK inhibitors are daily oral pills. They work inside immune cells rather than intercepting proteins outside them, blocking a family of enzymes called Janus kinases that relay the signals triggering inflammation. The approved JAK inhibitors for RA include tofacitinib, baricitinib, upadacitinib, and filgotinib.

Both types come into play when methotrexate — the standard first drug for RA — has not controlled the disease well enough on its own [4].

At a glance

How TNF inhibitors established the track record

The case for biologic therapy in RA rests on trials that go back nearly 30 years. Larry Moreland, now a professor at the University of Colorado School of Medicine, led some of the earliest. A 1997 study he led in the New England Journal of Medicine tested etanercept — a protein that intercepts TNF — in 180 patients with refractory RA. At the highest dose, 75% of patients had meaningful improvement in symptoms versus 14% on placebo. The main side effects were mild injection-site reactions [9]. Two years later, a follow-up study confirmed etanercept could provide rapid, significant, and sustained benefit in active disease [10].

A trial of 632 patients with early RA published in 2000 compared etanercept directly to methotrexate. Etanercept worked faster — more patients had 20%, 50%, and 70% symptom improvements in the first six months. At twelve months, joint erosion (measured on imaging) was roughly half what it was in the methotrexate group [7].

The same pattern appeared with adalimumab. The ARMADA trial added adalimumab to the regimens of 271 patients who were still active despite methotrexate. At the 40 mg dose, 67% reached the standard response threshold versus 15% on placebo [8]. These studies gave biologics a safety and efficacy record that no other drug class in RA could match at the time.

Where JAK inhibitors fit in

JAK inhibitors arrived later and offered something biologics could not: a pill. For patients who struggle with injections, that matters. For patients managing multiple conditions with complex dosing schedules, a single daily tablet can simplify things.

Early guidelines positioned JAK inhibitors alongside biologics as roughly equivalent options when methotrexate is not enough. The 2019 EULAR recommendations — developed by 47 institutions across 18 countries, including rheumatologists and patient representatives — stated that both biologic DMARDs and JAK inhibitors are appropriate next steps after conventional therapy fails, without strong grounds to prefer one over the other in most patients [1].

That position has since been revised.

The safety picture shifts after 2020

The 2022 EULAR update added explicit language that was absent in earlier versions. The task force now requires doctors to weigh three specific risks before prescribing a JAK inhibitor: major adverse cardiovascular events (MACEs — heart attack and stroke), thromboembolic events (blood clots, including deep vein thrombosis and pulmonary embolism), and malignancies [2].

The updated guidance states that when patients with poor prognostic factors need to move beyond methotrexate, a biologic should generally be added first. JAK inhibitors "may also be considered" — but only "after careful consideration" of those risks [2].

The 2021 ACR guideline made similar moves. Across 44 recommendations, JAK inhibitors received additional scrutiny in patients with specific medical histories: heart failure, lymphoproliferative disorders, and serious or recurrent infections [3].

The evidence driving all of this came largely from a trial called ORAL Surveillance, which enrolled patients over 50 with at least one cardiovascular risk factor and compared tofacitinib to TNF inhibitors. ORAL Surveillance found higher rates of MACEs and certain cancers in patients receiving tofacitinib. The FDA responded with a black-box warning on all JAK inhibitors, and both EULAR and ACR updated their guidance accordingly [2][3].

Who should be more cautious with JAK inhibitors

Based on current guidelines, your doctor is likely to recommend starting with a biologic rather than a JAK inhibitor if you have any of the following:

• Age 65 or older, especially with cardiovascular risk factors like high blood pressure, high cholesterol, diabetes, or smoking history
• A personal history of heart attack or stroke
• Elevated risk for blood clots, or a recent clotting event
• A history of cancer, particularly blood cancers like lymphoma
• Active serious infections or a pattern of frequent infections

If none of those apply — if you are relatively young, your heart health is well controlled, and you have no cancer history — then current guidelines from both EULAR and ACR treat biologics and JAK inhibitors as broadly comparable alternatives [1][2][3]. Your preferences, insurance coverage, and willingness to inject yourself play a genuine role in the decision.

What both classes share: infection risk

Infection risk is the one safety concern that applies equally to both options. JAK inhibitors do not have a clearly worse infection profile than biologics for most patients — both raise your risk of serious bacterial infections, and both can reactivate latent tuberculosis.

Before starting either a biologic or a JAK inhibitor, your doctor will screen you for latent TB, check your blood counts, and test your liver function. Once you're on treatment, repeat labs are done every three to six months [5][6]. Guidelines covering biologic monitoring in arthritis patients consistently follow this pattern — baseline labs, TB testing before starting, then regular follow-up throughout [11].

If you've lived in or traveled to a region with high TB rates, or had close contact with someone with TB, tell your rheumatologist before you start either medication.

What monitoring looks like day to day

On a biologic, routine monitoring typically includes:

• TB skin test or blood test before starting
• Blood count and liver function labs at baseline, then every 3 to 6 months
• Watching for injection-site reactions (usually mild and temporary)
• Infusion reactions if you're on an IV biologic, managed by the infusion center

On a JAK inhibitor, the baseline labs are the same, with two additions. Your doctor will check a fasting lipid panel — JAK inhibitors raise cholesterol modestly in some patients — and will monitor cardiovascular symptoms more closely if you have relevant risk factors. Prior cancer history triggers additional review as well.

Once you're stable on either drug class, lab monitoring is fairly routine — typically a blood draw every three to six months, the same schedule you'd follow on other disease-modifying drugs.

Questions to ask your doctor

• Given my age and heart health, do the JAK inhibitor safety warnings apply to me specifically?
• Do I have any history that makes a biologic the safer first step beyond methotrexate?
• If injections are a barrier for me, is a pill-based option still reasonable in my situation?
• What TB screening do I need before we start?
• How will we monitor for the specific risks of whichever drug we choose?
• If the first biologic or JAK inhibitor does not control my disease, can we switch between classes?

The bottom line

Both biologics and JAK inhibitors can control RA effectively when methotrexate is not enough. The difference lies in their risk profiles. Biologics have a longer track record and, in older patients with cardiovascular risk factors, a cleaner safety record. JAK inhibitors offer the convenience of a daily pill but carry additional concerns about heart attack, blood clots, and certain cancers in patients who already have those risk factors.

Current guidelines from EULAR and ACR generally recommend starting with a biologic when you need to escalate, with JAK inhibitors as a reasonable option in patients who do not have the high-risk profile or who have a specific reason to prefer an oral medication [1][2][3]. The guidelines have changed meaningfully since 2020, so it is worth asking your rheumatologist whether they are using the most recent version when they explain your options.